Charles River Laboratories International, Inc. — Q1 2024 Form 10-Q
Reporting period: 13 weeks ended March 30, 2024; comparable period ended April 1, 2023. The company provides nonclinical drug-development services, research models and products, and manufacturing-related services through RMS, DSA, and Manufacturing.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $1,011.6 million | $1,029.4 million | Down 1.7% |
| Operating income | $126.0 million | $167.9 million | Down 25.0% |
| Operating margin | 12.5% | 16.3% | Down 380 basis points |
| Net income attributable to Charles River | $73.0 million | $103.1 million | Down |
| Diluted EPS | $1.30 | $2.01 | Down |
| Operating cash flow | $129.9 million | $109.4 million | Up |
| Capital expenditures | $79.1 million | $106.9 million | Down |
Service revenue declined 4.7% to $816.9 million; product revenue increased 13.2% to $194.7 million. Net income available to common shareholders was $67.3 million after $5.6 million of adjustments and preferential dividends attributable to redeemable noncontrolling interests, compared with $103.1 million in Q1 2023.
Segments
| Segment | Revenue | Year-over-year change | Operating income | Operating margin |
|---|---|---|---|---|
| RMS | $220.9 million | Up 10.6% | $43.1 million | 19.5%, down 70 bps |
| DSA | $605.5 million | Down 8.6% | $114.8 million | 19.0%, down 690 bps |
| Manufacturing | $185.2 million | Up 10.7% | $33.7 million | 18.2%, up 1,690 bps |
DSA’s lower volume in Discovery Services and Safety Assessment was the principal drag on consolidated revenue and profit. Manufacturing’s improvement reflected higher service and product volumes, operational efficiencies, and the absence of prior-year impairment and legal costs. RMS growth was supported by Noveprim, which contributed $15.1 million of revenue.
Liquidity, debt, and cash flow
At March 30, 2024, cash and cash equivalents were $327.0 million; cash, cash equivalents, and short-term investments totaled $337.1 million. Long-term debt, net, and finance leases were $2.66 billion, including $1.13 billion drawn on the revolving facility and $1.50 billion of senior notes. The weighted-average debt interest rate was 4.97%. Total current liabilities were $954.8 million. The company reports that existing funds, operating cash flows, and financing access are sufficient to fund operations for the foreseeable future.
Operating cash flow increased year over year, which management attributed mainly to timing of supplier payments and improved revenue-related working-capital accounts. Investing cash outflow was $85.8 million, including $79.1 million of capital expenditures; financing cash inflow was $18.3 million. Cash, cash equivalents, and restricted cash ended the quarter at $338.5 million. The company had $21.2 million in outstanding letters of credit and a $500 million interest-rate swap at a fixed 4.65% rate maturing November 2, 2024.
Material changes and unusual items
- Consolidated revenue fell 1.7%, while operating income declined 25.0%; management cited DSA volume weakness, higher staffing and operating costs, and restructuring charges.
- The effective tax rate rose to 24.8% from 20.7%, primarily due to unfavorable tax effects from stock-based compensation deductions.
- Other income included $8.2 million of venture-capital investment gains, compared with $6.8 million of losses a year earlier; strategic equity investments recorded a $2.3 million loss.
- Restructuring charges were $17.0 million, comprising $9.0 million of severance and transition costs and $8.0 million of asset impairments and other costs. Management expects completed and planned actions to generate approximately $70 million in annualized cost savings.
- Foreign-currency translation contributed to a $61.7 million pretax other comprehensive loss; accumulated other comprehensive loss increased to $249.9 million.
Outlook, risks, and contingencies
The filing provides no specific revenue, earnings, or EPS guidance. Management’s stated outlook includes approximately $70 million in annualized savings from restructuring actions and confidence in funding operations for the foreseeable future. The company reported $920.5 million of remaining performance obligations, approximately 50% expected to be recognized within 12 months; this figure excludes certain short-term and other specified contracts.
Material uncertainties include DOJ and U.S. Fish and Wildlife Service investigations, and a separate SEC inquiry, concerning Cambodian non-human-primate shipments. The company has suspended future shipments from Cambodia to the U.S. pending agreement on additional procedures and is cooperating with authorities. It held approximately $27 million of related inventory at quarter-end. The company cannot predict the investigations’ outcome or potential fines, penalties, or liabilities.
A securities class action relating to disclosures about non-human-primate imports is pending; the company has moved to dismiss and says it cannot reasonably estimate potential exposure. A related shareholder derivative suit is stayed pending a ruling on the class-action dismissal motion. The company says it intends to defend both matters. It also disclosed that its 10% Noveprim noncontrolling interest may receive preferential dividends and is subject to purchase options; these provisions reduced Q1 common-shareholder earnings by $5.2 million.
Most important facts for investors to verify
- Whether DSA demand and volume stabilize, given its 8.6% revenue decline and 690-basis-point margin contraction.
- Progress and realization of the approximately $70 million annualized restructuring savings, including execution costs and effects on capacity.
- Updates on the Cambodian NHP investigations, import procedures, litigation, and the carrying value and usability of the related $27 million inventory.
- Debt levels, revolving-facility borrowing costs, and refinancing or interest-rate exposure, including the November 2024 swap maturity.
- How Noveprim’s preferential dividends and redemption terms affect common-shareholder earnings and future cash requirements.